Pyc Therapeutics Ltd has released a press release.
ADOA Safety Review Committee Approves Dose Escalation
Filed with ASX ·
6ix hasn’t read this filing yet.
PYC Therapeutics Limited on 6ix
Story so far
Earlier from PYC Therapeutics
- US FDA Grants Rare Pediatric Disease Designation to VP-001
- PYC Nominates Fourth Clinical Drug Candidate in PMS Program
- PYC to Progress Kidney Drug Candidate Into Human Trials
- Consolidation/Split - PYC
- RP11 SRC Approves Dose Escalation to Final Patient Cohort
Later from PYC Therapeutics
- Approval to Commence Human Trials in Kidney Program
- PYC Equity Raising to Raise up to $146 Million
- PYC Equity Raising Presentation
- Completion of Institutional Entitlement Offer
- Retail Entitlement Offer Booklet
Follow PYC Therapeutics into a list and get an email when it puts out news.
Follow PYC Therapeutics